as 07-26-2024 4:00pm EST
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Founded: | 2008 | Country: | United States |
Employees: | N/A | City: | SOUTH SAN FRANCISCO |
Market Cap: | 100.5M | IPO Year: | 2015 |
Target Price: | $5.77 | AVG Volume (30 days): | 902.8K |
Analyst Decision: | Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.20 | EPS Growth: | N/A |
52 Week Low/High: | $1.04 - $5.85 | Next Earning Date: | 08-06-2024 |
Revenue: | $119,178,000 | Revenue Growth: | 76.24% |
Revenue Growth (this year): | 3.67% | Revenue Growth (next year): | -25.58% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
ROWLAND LLOYD A | CTMX | General Counsel | Mar 19 '24 | Sell | $2.09 | 5,268 | $10,986.41 | 117,728 | SEC Form 4 |
McCarthy Sean A. | CTMX | CEO | Mar 19 '24 | Sell | $2.09 | 20,223 | $42,175.07 | 524,481 | SEC Form 4 |
BELVIN MARCIA | CTMX | SVP, Chief Scientific Officer | Mar 19 '24 | Sell | $2.09 | 12,795 | $26,683.97 | 168,579 | SEC Form 4 |
Landau Jeffrey B | CTMX | Chief Business Officer | Mar 19 '24 | Sell | $2.09 | 6,562 | $13,685.05 | 110,060 | SEC Form 4 |
Ogden Christopher | CTMX | SVP, Finance and Accounting | Mar 19 '24 | Sell | $2.09 | 2,971 | $6,196.02 | 85,686 | SEC Form 4 |
BELVIN MARCIA | CTMX | SVP, Chief Scientific Officer | Dec 20 '23 | Sell | $1.38 | 4,077 | $5,628.30 | 155,124 | SEC Form 4 |
McCarthy Sean A. | CTMX | CEO | Dec 20 '23 | Sell | $1.38 | 13,551 | $18,709.87 | 454,704 | SEC Form 4 |
Landau Jeffrey B | CTMX | Chief Business Officer | Dec 20 '23 | Sell | $1.38 | 4,077 | $5,628.30 | 86,622 | SEC Form 4 |
ROWLAND LLOYD A | CTMX | General Counsel | Dec 20 '23 | Sell | $1.38 | 4,077 | $5,629.11 | 97,996 | SEC Form 4 |
Ogden Christopher | CTMX | SVP, Finance and Accounting | Dec 20 '23 | Sell | $1.38 | 1,990 | $2,747.39 | 48,657 | SEC Form 4 |
CTMX Breaking Stock News: Dive into CTMX Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Simply Wall St.
5 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
Simply Wall St.
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
Insider Monkey
3 months ago
The information presented on this page, "CTMX CytomX Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.